Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03747523 · ClinicalTrials.gov registry record · Early Phase 1
Pilot Study: The Effect of Ergocalciferol on Plasma Mucin-1 Levels
A Early Phase 1 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 44
- Enrollment target
NCT03747523 is a Early Phase 1 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 44 participants.
The verdict
NCT03747523, a Early Phase 1 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 44 participants
- Enrollment target
Study Summary
To determine if a one-time oral administration of ergocalciferol results in a decline in plasma mucin-1 levels in healthy individuals and individuals with ADTKD-MUC1.
Interventions
- DRUG Ergocalciferol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2019-03-12 |
| Est. Completion | 2020-01-27 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03747523
The ClinicalTrials.gov registry entry for NCT03747523 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ergocalciferol is the first listed.
NCT03747523 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03747523 about?
NCT03747523 is a clinical study titled "Pilot Study: The Effect of Ergocalciferol on Plasma Mucin-1 Levels". To determine if a one-time oral administration of ergocalciferol results in a decline in plasma mucin-1 levels in healthy individuals and individuals with ADTKD-MUC1.
What is the current status of trial NCT03747523?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 44 participants. The study started on 2019-03-12. Estimated completion is 2020-01-27.
What interventions are being tested in trial NCT03747523?
The interventions under investigation include: Ergocalciferol (DRUG).
Who is sponsoring clinical trial NCT03747523?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.